Real-life Treatment Outcomes of Ravulizumab in PNH
NCT06633536 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 64
Last updated 2026-04-01
Summary
The PNH-RECORD study, a Polish multicenter observational (non-interventional), open-label, retrospective with prospective follow-up.
Conditions
- Paroxysmal Nocturnal Haemoglobinuria
Interventions
- DRUG
-
Ravulizumab
open-label arm with ravulizumab administrated within the scope of routine clinical practice
Sponsors & Collaborators
- lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-02-06
- Primary Completion
- 2028-08-01
- Completion
- 2028-08-01
- FDA Drug
- Yes
Countries
- Poland
Study Locations
More Related Trials
-
Sirolimus Combined With Low-dose Warfarin for the Treatment of Refractory PNH
NCT03866681 ·Status: UNKNOWN ·Phase: PHASE4
-
REAL-CARE: Real-world Effectiveness of Iptacopan in Italian Patients With Paroxysmal Nocturnal Hemoglobinuria
NCT07229235 ·Status: RECRUITING
-
Ruxolitinib for Polycythemia Vera in Patients Resistant to or Intolerant of Hydroxyurea.
NCT05421104 ·Status: COMPLETED
-
Study of Global Coagulation Tests in Patients With Paroxysmal Nocturnal Haemoglobinuria
NCT01020188 ·Status: COMPLETED
-
Natural History Study of Adult Patients With Paroxysmal Nocturnal Hemoglobinuria of High-risk Hemolysis in China
NCT05125341 ·Status: COMPLETED
-
Paroxysmal Nocturnal Hemoglobinuria Human Anti-Human Antibodies Study
NCT01412047 ·Status: COMPLETED
-
Long-term Safety and Tolerability of MY008211A Tablets in Patients With Paroxysmal Nocturnal Hemoglobinuria
NCT06933914 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Study of Safety and Efficacy of MY008211A in in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT06134414 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Paroxysmal Nocturnal Hemoglobinuria (PNH), Level of CD59 on Red and White Blood Cells in Bone Marrow Failure Syndromes
NCT01192425 ·Status: COMPLETED
-
Pharmacokinetics of Oral Hydroxyurea Solution
NCT03763656 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of MY008211A in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT06050226 ·Status: COMPLETED ·Phase: PHASE2
-
Long-term Safety and Tolerability of HSK39297 in Patients With Paroxysmal Nocturnal Hemoglobinuria
NCT06745622 ·Status: RECRUITING ·Phase: PHASE2
-
MAP to Provide Access to Ruxolitinib, for Patients With Polycythemia Vera
NCT05269771 ·Status: NO_LONGER_AVAILABLE
-
Microvascular and Cardiac Dysfunction in Paroxysmal Nocturnal Hemoglobinuria and Sickle Cell Disease
NCT01294891 ·Status: COMPLETED
-
Electronic Patient-reported Outcome Monitoring in Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria
NCT04128943 ·Status: COMPLETED
-
Extension Study of RA101495 for Patients With PNH Who Have Completed a Zilucoplan (RA101495) Clinical Study
NCT03225287 ·Status: TERMINATED ·Phase: PHASE2
-
Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Classic Paroxysmal Nocturnal Hemoglobinuria
NCT01642979 ·Status: UNKNOWN ·Phase: PHASE2
-
Multicenter Retrospective Analysis About the Clinical Characteristics of Korean Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients
NCT01224483 ·Status: UNKNOWN
-
Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Subclinical Paroxysmal Nocturnal Hemoglobinuria and PNH in the Setting of Another Bone Marrow Failure Syndromes(PNH-2013)
NCT01760096 ·Status: UNKNOWN ·Phase: PHASE2
-
Ropeginterferon Alfa-2b in Patients With Polycythemia Vera (PV) Without Symptomatic Splenomegaly
NCT06743035 ·Status: RECRUITING
-
A Phase II Trial of Regadenoson in Sickle Cell Anemia
NCT01788631 ·Status: COMPLETED ·Phase: PHASE2
-
Phase I Study to Examine the Effect of Deferasirox on Renal Hemodynamics in β-thalassemia Patients With Transfusional Iron Overload
NCT00560820 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Evaluate the Efficacy and Safety of Deferasirox Film-coated Tablet Versus Phlebotomy in Patients With Hereditary Hemochromatosis (HH)
NCT03203850 ·Status: TERMINATED ·Phase: PHASE2
-
Transfer of GPI-Linked Proteins to Transfused Patients With Paroxysmal Nocturnal Hemoglobinuria
NCT00039923 ·Status: COMPLETED
-
Optimizing Hydroxyurea Dosage With Pharmakokinetic in Patients Suffering of Moderate to Severe Sickle Cell Anemia
NCT06761560 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2/PHASE3